| Literature DB >> 25515341 |
Farooq Nasar1,2, Andrew D Haddow3, Robert B Tesh4, Scott C Weaver5.
Abstract
BACKGROUND: Most alphaviruses are arthropod-borne and utilize mosquitoes as vectors for transmission to susceptible vertebrate hosts. This ability to infect both mosquitoes and vertebrates is essential for maintenance of most alphaviruses in nature. A recently characterized alphavirus, Eilat virus (EILV), isolated from a pool of Anopheles coustani s.I. is unable to replicate in vertebrate cell lines. The EILV host range restriction occurs at both attachment/entry as well as genomic RNA replication levels. Here we investigated the mosquito vector range of EILV in species encompassing three genera that are responsible for maintenance of other alphaviruses in nature.Entities:
Mesh:
Year: 2014 PMID: 25515341 PMCID: PMC4297418 DOI: 10.1186/s13071-014-0595-2
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Figure 1Comparison of plaque size (A) and replication kinetics (B) of EILV and EILV-eRFP in C7/10 cells (+/−S.D.).
Figure 2Stability of eRFP cassette in C7/10 cells after five serial passages. Phase-contrast and fluorescent photographs of passage one and five infection in C7/10 cells are shown.
Stability of eRFP cassette in C7/10 cells after five serial passages
|
| ||
|---|---|---|
|
|
|
|
|
| ||
| Passage #1 | 6.1 (+/− 0.18) | 99 |
| Passage #5 | 6.5 (+/− 0.20) | 90 |
Virus titers for passage one and five were generated with standard plaque assay. Percent of plaques expressing eRFP was determined by counting plaques expressing eRFP via fluorescent microscope and crystal violet staining.
Figure 3EILV-eRFP infection of the posterior midgut 7 dpi in mosquitoes infected via IT route at 10 PFU/mL. Phase-contrast and fluorescent photographs were taken at 10X magnification.
EILV-eRFP infection of various mosquito organs 7 dpi
|
|
|
| |||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |
|
| 7.3 | 50 | 100 | 30 | 90 | 30 | 0 |
|
| 7.3 | 30 | 100 | 10 | 90 | 0 | 0 |
|
| 7.3 | 0 | 70 | 0 | 0 | 0 | 0 |
|
| 7.3 | 10 | 90 | 10 | 70 | 0 | 0 |
10 mosquitoes/species were visualized with fluorescent microscopy.
Figure 4EILV-eRFP infection of the salivary glands 7 dpi in mosquitoes infected via IT route at 10 PFU/mL. Phase-contrast and fluorescent photographs were taken at 10X magnification.
Figure 5EILV-eRFP infection of the anterior midgut (A) and Malpighian tubules (B) 7 dpi in mosquitoes infected via IT route at 10 PFU/mL. Phase-contrast and fluorescent photographs were taken at 10X magnification.
Figure 6EILV infection of mosquitoes injected via IT route at 10 PFU/mosquito. N = 5 for each time point.
Mosquito infection dose 50 (ID ) via IT route
|
|
| ||
|---|---|---|---|
|
|
| ||
|
|
| ||
|
|
| ||
|
| |||
|
| 4.5 (+/− 0.16) | 100 | 4.6 (+/− 0.15) |
| 3.7 (+/− 0.11) | 100 | 4.9 (+/− 0.07) | |
| 2.4 (+/− 0.26) | 100 | 4.9 (+/− 0.08) | |
| 1.3 (+/− 0.29) | 100 | 4.8 (+/− 0.15) | |
|
| 4.3 (+/− 0.21) | 100 | 4.3 (+/−0.18) |
| 3.3 (+/− 0.14) | 100 | 4.6 (+/− 0.25) | |
| 2.3 (+/−0.43) | 100 | 4.5 (+/− 0.14) | |
| 1.0* | 100 | 4.4 (+/− 0.19) | |
|
| 4.0 (+/− 0.18) | 100 | 3.9 (+/− 0.43) |
| 2.8 (+/− 0.18) | 100 | 4.1 (+/− 0.22) | |
| 1.8 (+/− 0.38) | 100 | 4.1 (+/− 0.15) | |
| 1.0* | 100 | 4.3 (+/− 0.04) | |
|
| 4.1 (+/− 0.18) | 100 | 4.2 (+/− 0.25) |
| 3.1 (+/− 0.12) | 100 | 4.2 (+/− 0.24) | |
| 1.8 (+/− 0.30) | 100 | 4.1 (+/− 0.30) | |
| 1.0* | 100 | 4.2 (+/− 0.31) | |
Mosquitoes were injected at doses ranging from 104-101 PFU/mosquito of EILV. Whole mosquitoes were analyzed post-injection and 7 dpi at each dose via plaques assays. N = 5 for each time point. *Samples were below the limit of detection (101 PFU/mosquito) for the plaque assay.
Oral infection of mosquitoes with EILV-eRFP
|
|
|
|
| ||
|---|---|---|---|---|---|
|
|
|
|
|
| |
|
|
| ||||
|
|
| ||||
|
| 8.9 | 78 (18/23) | 2.3 (+/− 0.87) | 26 (6/23) | 2.2 (+/− 0.73) |
| 6.9 | 63 (15/24) | 2.0 (+/− 0.83) | 8 (2/24) | 1.5 (+/−0.34) | |
| 5.0 | 0 (0/15) | ND | 0 (0/15) | ND | |
|
| 8.9 | 7 (2/27) | 1.5(+/− 0.16) | 0 (0/27) | 1.0* |
| 6.9 | 8 (2/24) | 1.5(+/− 0.19) | 0 (0/24) | 1.0* | |
| 5.0 | 0 (0/31) | ND | 0 (0/31) | ND | |
|
| 8.8 | 29 (4/14) | 1.6 (+/− 0.36) | 21 (3/14) | 1.4 (+/−0.10) |
| 6.9 | 4 (1/23) | 1.3 | 4 (1/23) | 1.3 | |
| 5.7 | 0 (0/15) | ND | 0 (0/15) | ND | |
|
| 9.0 | 30 (9/30) | 1.6 (+/− 0.55) | 30 (9/30) | 1.5 (+/− 0.24) |
| 7.7 | 0 (0/28) | 1.0* | 0 (0/28) | 1.0* | |
| 5.8 | 0 (0/30) | ND | 0 (0/30) | ND | |
Mosquito bodies and legs/wings were analyzed for eRFP expression and plaques assays in C7/10 cells. *Samples were below the limit of detection (101 PFU/mosquito) for the plaque assay.
Comparison body infection rates via eRFP expression, plaque assay, and RT-PCR
|
|
|
| ||
|---|---|---|---|---|
|
|
|
|
| |
|
| 8.9 | 78 (18/23) | 78 (18/23) | 87 (20/23) |
|
| 8.9 | 7 (2/27) | 7 (2/27) | 15 (4/27) |
|
| 8.9 | 29 (4/14) | 29 (4/14) | 43 (6/14) |
|
| 8.9 | 30 (9/30) | 30 (9/30) | 30 (9/30) |
Percent of mosquito bodies positive at 14 dpi.